|Bid||230.00 x 1000|
|Ask||230.99 x 800|
|Day's Range||230.26 - 236.58|
|52 Week Range||107.44 - 242.14|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||243.00|
Dexcom said Q4 revenue was well above consensus. Gave 2020 revenue guidance that was above views at the midpoint. The glucose monitoring device maker pullback sharply in the morning below a 232.10 entry, but slashed losses.
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference. Arrowhead Pharma stock is testing key support.
Dexcom stock is the IBD Stock Of The Day after shares of the diabetes treatment specialist broke out of a flat base to a record high. Dexcom makes devices for patients with diabetes.
Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Dow futures dived on an Iranian missile attack vs. Iraqi bases with U.S. troops, but erased huge losses as President Trump tweeted "All is well!"
The IBD SmartSelect Composite Rating for Dexcom rose from 94 to 97 Tuesday. The revised score for the maker of glucose monitoring systems for diabetics means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
Futures: Software has rejoined stock market rally, as Salesforce, Dynatrace and Rapid7 broke out. Vertex, Dexcom, Insulet staged bullish rebounds.
The legal battle between WaveForm Technologies and a much larger competitor has now moved to the U.S. Court of Appeals for the Federal Circuit, after the Wilsonville medical device maker lost a round in U.S. District Court in Oregon. U.S. District Judge Michael Mosman granted summary judgment to Dexcom Inc. in August. WaveForm, which sued Dexcom for patent infringement related to its continuous glucose monitoring device, is now appealing that ruling.